BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

...Paul Scigalla as CMO on a consultancy basis. Scigalla is CMO of oncolytic virus company Genelux Corp....
BioCentury | Aug 15, 2016
Clinical News

GLV-1h68: Phase Ib started

...days or escalating doses of 2x10 9-5x10 9 PFUs of GL-ONC1 given for 5 days. Genelux Corp....
BioCentury | Aug 15, 2016
Clinical News

GLV-1h68: Phase Ib started

...U.S. Phase Ib trial to evaluate GL-ONC1 given via intraperitoneal infusion in about 12 patients. Genelux Corp....
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. DNAtrix Inc., Houston, Texas Genelux Corp....
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

...dosing the HDAC inhibitor, the tumor cell expresses the CAR much more," he said. Similarly, Genelux Corp....
...and Genentech Inc .'s Avastin bevacizumab to increase tumor uptake of GL-ONC1 ( GLV-1h68 ). Genelux...
...companion imaging. It is in Phase I/II testing to treat platinum-resistant ovarian cancer. Zindrick said Genelux...
BioCentury | Jun 1, 2015
Clinical News

GLV-1h68: Phase I data

...epithelioid MPM. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Genelux Corp....
BioCentury | Jun 1, 2015
Clinical News

GLV-1h68: Phase I data

...been reached. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Genelux Corp....
BioCentury | May 19, 2014
Company News

Genelux management update

Genelux Corp. , San Diego, Calif. Business: Cancer, Diagnostic Retiring: Aldard Szalay as president, CEO and chairman; he is succeeded as chairman by James Tyree, a director, and as president and CEO by Thomas Zindrick, formerly...
BioCentury | Feb 17, 2014
Company News

Genelux management update

Genelux Corp. , San Diego, Calif. Business: Cancer, Diagnostic Hired: John Prunty as CFO, formerly SVP, corporate secretary and CFO of Optimer Pharmaceuticals Inc., which Cubist Pharmaceuticals Inc. acquired WIR Staff cancer Diagnostic...
BioCentury | Jul 1, 2013
Company News

Genelux management update

...San Diego, Calif. Business: Cancer, Diagnostic Hired: Stefan Manth as president and CEO of Genelux...
Items per page:
1 - 10 of 21
BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

...Paul Scigalla as CMO on a consultancy basis. Scigalla is CMO of oncolytic virus company Genelux Corp....
BioCentury | Aug 15, 2016
Clinical News

GLV-1h68: Phase Ib started

...days or escalating doses of 2x10 9-5x10 9 PFUs of GL-ONC1 given for 5 days. Genelux Corp....
BioCentury | Aug 15, 2016
Clinical News

GLV-1h68: Phase Ib started

...U.S. Phase Ib trial to evaluate GL-ONC1 given via intraperitoneal infusion in about 12 patients. Genelux Corp....
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. DNAtrix Inc., Houston, Texas Genelux Corp....
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

...dosing the HDAC inhibitor, the tumor cell expresses the CAR much more," he said. Similarly, Genelux Corp....
...and Genentech Inc .'s Avastin bevacizumab to increase tumor uptake of GL-ONC1 ( GLV-1h68 ). Genelux...
...companion imaging. It is in Phase I/II testing to treat platinum-resistant ovarian cancer. Zindrick said Genelux...
BioCentury | Jun 1, 2015
Clinical News

GLV-1h68: Phase I data

...epithelioid MPM. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Genelux Corp....
BioCentury | Jun 1, 2015
Clinical News

GLV-1h68: Phase I data

...been reached. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Genelux Corp....
BioCentury | May 19, 2014
Company News

Genelux management update

Genelux Corp. , San Diego, Calif. Business: Cancer, Diagnostic Retiring: Aldard Szalay as president, CEO and chairman; he is succeeded as chairman by James Tyree, a director, and as president and CEO by Thomas Zindrick, formerly...
BioCentury | Feb 17, 2014
Company News

Genelux management update

Genelux Corp. , San Diego, Calif. Business: Cancer, Diagnostic Hired: John Prunty as CFO, formerly SVP, corporate secretary and CFO of Optimer Pharmaceuticals Inc., which Cubist Pharmaceuticals Inc. acquired WIR Staff cancer Diagnostic...
BioCentury | Jul 1, 2013
Company News

Genelux management update

...San Diego, Calif. Business: Cancer, Diagnostic Hired: Stefan Manth as president and CEO of Genelux...
Items per page:
1 - 10 of 21